Genzyme has done it before with Genzyme tissue repair and GZMO. A little different because of tracking company status which we don't exactly have. In theory Genz as a large corporate owner of GTCB stock could be forcing downward pressure on the stock by selling now to perhaps get a better deal for atryn or take over. Dew?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.